K-numberK250040
Device nameuWS-Angio
ApplicantShanghai United Imaging Healthcare Co., Ltd.
Product codeLLZ
Device classClass II
Decision dateSep 12, 2025
DecisionSubstantially Equivalent
Regulation892.2050
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

uWS-Angio is post-processing software for viewing, processing, evaluating and analyzing XA (x-ray angiography) images compliant with DICOM 3.0 standard. It provides four applications: 2D Vessel Analysis for quantifying coronary and peripheral vessel dimensions, Left Ventricular Analysis for assessing cardiac function and wall motion, 2D Blood Flow Analysis for analyzing blood flow parameters in peripheral vessels, and Stitching for combining overlapping lower extremity images into a single visualization.

Technological characteristics

uWS-Angio is a software-only device with the same classification, product code (LLZ), and regulatory framework (21 CFR 892.2050, Class II) as the predicate. While the proposed device includes fewer total applications than the predicate device (syngo Application Software), the individual functions present—vessel contour extraction, contour editing, left ventricular volume and wall motion calculations, and ROI-based blood flow parameters—are substantially equivalent. The device adds some parameters (Arrival Time, Wash-in Rate, Rise Time) calculated from time-density curves, but these differences do not impact safety or effectiveness.

Test standards cited

NEMA PS 3.1-3.20 (DICOM 2023e), ISO 14971 (risk management), IEC 62304 (software life cycle), and FDA guidance on cybersecurity in medical devices and device software functions. Testing included software verification and validation, hazard analysis, and performance verification across phantom studies, clinical case comparisons, and simulated datasets.

Substantial equivalence argument

The device is substantially equivalent because it shares the same intended use (post-processing and analysis of angiographic images in healthcare settings), same regulatory classification and product code, and operates on the same fundamental scientific principles as the predicate. Performance verification demonstrated that vessel diameter measurements achieve 1.1–2.1% mean relative error, left ventricular volume calculations align with ground truth within acceptable limits of agreement, blood flow parameters achieve ICC >0.998 in simulation studies, and image stitching achieves sub-pixel registration accuracy. These safety and efficacy profiles are comparable to the predicate device despite minor functional differences that do not raise new safety concerns.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →